
| Pair Name | Parthenolide, Doxorubicin | ||
| Phytochemical Name | Parthenolide (PubChem CID: 7251185 ) | ||
| Anticancer drug Name | Doxorubicin (PubChem CID: 31703 ) | ||
| Structure of Phytochemical |
Download
2D
MOL
3D
MOL
|
||
| Structure of Anticancer Drug |
Download
2D
MOL
3D
MOL
|
||
| Pair Name | Parthenolide, Doxorubicin | |||
| Disease Info | [ICD-11: 2C60] | Breast cancer | Investigative | |
| Biological Phenomena | Inhibition-->Overexpression of both Nrf2 and its target activities | |||
| Gene Regulation | Down-regulation | Expression | NFE2L2 | hsa4780 |
| Down-regulation | Expression | HSPA4 | hsa3308 | |
| Down-regulation | Expression | BCL2 | hsa596 | |
| Down-regulation | Expression | SOD2 | hsa6648 | |
| In Vitro Model | MDA-MB-231 | Breast adenocarcinoma | Homo sapiens (Human) | CVCL_0062 |
| Result | PN prevented the acquisition of resistance induced by Mitox and DOX treatment in MDA-MB231 cells. This effect was mediated by inhibition of overexpression of both Nrf2 and its target activities. Therefore, within MDA-MB231 cell lines, PN not only exerts toxic effects on stem-like cells, which are responsible for tumour recurrence, but also prevents drug resistance | |||
| No. | Title | Href |
|---|---|---|
| 1 | Parthenolide prevents resistance of MDA-MB231 cells to doxorubicin and mitoxantrone: the role of Nrf2. Cell Death Discov. 2017;3:17078. Published 2017 Dec 4. doi:10.1038/cddiscovery.2017.78 | Click |